date:May 15, 2014
2013.
The net loss attributable to common stock holders for Q1 2014 was $1,848,016 or ($0.02) per share as compared to a net loss of $1,424,072 or ($0.02) per share for Q1 2013.
Over the past three years, we have spent considerable capital and resources to commercialize what we believe are valuable, patented ingredient technologies - such as our NIAGEN nicotinamide riboside and PURENERGY caffeine alternative. The 97% increase in ingredient sales was largely a result of the first order we re